













|
|
Lee G. Beckwith, Jessica L. Moore, Gladys S. Tsao-Wu, John C. Harshbarger,
and Keith C. Cheng
|
| |
Jake
Gittlen Cancer Research Institute, Department of Pathology (LGB, JLM, KCC),
Department of Surgery (GST-W), and Department of Biochemistry and Molecular
Biology (KCC), Pennsylvania State University College of
Medicine, Hershey, Pennsylvania; and Registry of Tumors in Lower Animals,
Department of Pathology (JCH), George Washington University Medical Center,
Washington, D.C. |
| |
SUMMARY: The zebrafish (Danio rerio) has been successfully used
to discover hundreds of genes involved in development and organogenesis.
To address the potential of zebrafish as a cancer model, it is important
to determine the susceptibility of zebrafish to tumors. Germ line mutations
are most commonly induced for zebrafish mutant screens by exposing adult
male zebrafish to the alkylating agent, ethylnitrosourea (ENU). To determine
whether ENU induces tumors, we compared the incidence of tumors in ENU-treated
fish with untreated controls. Interestingly, 18 of 18 (100%) fish mutagenized
with either 2.5 or 3.0 mM ENU developed epidermal papillomas, which numbered
1 to 22 per fish, within 1 year of treatment. The induced epidermal lesions
included epidermal hyperplasia, flat papillomas (0.2 to 1.2 mm), and pedunculated
papillomas (1.2 to 8 mm in greatest dimension), but no skin cancers. Angiogenesis
was evident in papillomas larger than approximately 1 mm. All but two
papillomas contained the three cell types (keratinocytes, club, and mucous
cells) of normal zebrafish epidermis; histologic variants lacked either
club cells or mucous cells. Two cavernous hemangiomas and a single malignant
peripheral nerve sheath tumor were also found in the treated fish. None
of five untreated controls developed tumors. These studies establish the
feasibility of the zebrafish as an experimental model for the study of
skin tumors. (Lab Invest 2000, 80: 379-385)
|